Daryl Venable
Eli Lilly and Company
3 Papers
69 Citations
Daryl Venable is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Replicon & Hepatitis C virus. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor
Yip Yvonne Yee Mai,Frantz Victor,Jason Eric Lamar,Robert B. Johnson,Q. May Wang,Donna Barket,John I. Glass,Ling Jin,Lifei Liu,Daryl Venable,Mark Wakulchik,Congping Xie,Beverly A. Heinz,Elcira C. Villarreal,Joe Colacino,Nathan Yumibe,Mark Joseph Tebbe,John E. Munroe,Shu-Hui Chen +18 more
TL;DR: The design, syntheses and evaluation of a number of bicycloproline P2 bearing HCV protease inhibitors endowed with impressive enzyme potency, enzyme selectivity, cellular activity and favorable ADME profiles are described.
82
Cytoskeletal Requirements for Hepatitis C Virus (HCV) RNA Synthesis in the HCV Replicon Cell Culture System
TL;DR: The data demonstrate that HCV replication complex-mediated RNA synthesis requires microtubule and actin polymerization.
81
Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system.
TL;DR: The use of type I interferon (IFN) in combination with ribvirin, to treat chronic hepatitis C virus (HCV) infection has many drawbacks that prevent widespread application, ultimately leading to a significant unmet clinical need.
72